ScinoPharm Taiwan, Ltd. (TPE:1789)

Market Cap	15.81B +12.0%
Revenue (ttm)	3.07B -4.0%
Net Income	37.73M -81.6%
EPS	0.05 -81.6%
Shares Out	790.74M
PE Ratio	419.18
Forward PE	n/a
Dividend	0.29 (1.45%)
Ex-Dividend Date	Jul 2, 2026

Volume	525,008
Open	19.95
Previous Close	19.90
Day's Range	19.65 - 20.00
52-Week Range	16.70 - 29.10
Beta	0.44
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 5, 2026

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract manufacturing, and small molecules and peptide contract development and manufacturing organization services. The company was incorporated in 1997 and is ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2025, ScinoPharm Taiwan's revenue was 3.16 billion, a decrease of -7.13% compared to the previous year's 3.41 billion. Earnings were 136.95 million, a decrease of -59.64%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 30, 2026

Data Sources Report a data error